CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Combined Biologic Therapy Targeting B Cells and Eosinophils in Relapsing Multiple Sclerosis and Severe Asthma: A Case Report of Ofatumumab and Mepolizumab
Provisionally accepted
- University of Foggia, Foggia, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The management of multiple sclerosis (MS) in patients with significant comorbidities such as severe asthma presents unique therapeutic challenges. We report a case of successful combined biologic therapy with ofatumumab and mepolizumab in a patient with relapsing MS and pre-existing severe eosinophilic asthma, highlighting the feasibility and safety of dual biologic therapy. To our knowledge, this is the first report of concomitant use of ofatumumab and mepolizumab in a patient with MS and severe eosinophilic asthma, documenting the safety of a non-standard combination strategy in a real-world clinical scenario.
Keywords: Multiple Sclerosis, combination therapy, Ofatumumab, Mepolizumab, monoclonalantibodies
Received: 24 May 2025; Accepted: 28 Nov 2025.
Copyright: © 2025 Zanghì, Di Filippo, Rutigliano, Avolio and D'AMICO. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: EMANUELE D'AMICO
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.